Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its Homechoice Claria automated peritoneal dialysis (APD) system, featuring the Sharesource connectivity platform. This innovative system is designed for both adult and pediatric patients, enhancing remote patient management and promoting home dialysis growth. With over 6 million home dialysis treatments facilitated by Sharesource in the U.S., the new system aims to improve patient education and care efficiency. Homechoice Claria is slated for U.S. availability in the coming weeks.
Baxter International Inc. (NYSE:BAX) will participate in the Evercore ISI 3rd Annual HealthCONx virtual conference on December 1, 2020. Chief Financial Officer Jay Saccaro is set to present at 11:20 a.m. Eastern Time. The presentation will be available live via webcast at www.baxter.com and will remain accessible for replay until May 30, 2021. Baxter, a leader in medical products, supports millions of patients globally with critical care and surgical solutions, emphasizing innovative healthcare advancements for over 85 years.
Summary not available.
Baxter International proposes to offer $650 million in senior notes due 2031, subject to market conditions. The offering targets qualified institutional buyers under Rule 144A and non-U.S. investors through Regulation S. The proceeds will be used to redeem $750 million of senior notes due 2025, which were issued in 2020. This strategic move aims to bolster Baxter’s balance sheet amidst market uncertainties. The notes won't be registered under the Securities Act initially and are offered privately. This press release does not constitute an offer to sell.
Baxter International Inc. (NYSE:BAX) reported third-quarter 2020 earnings with worldwide sales of $2.97 billion, a 4% increase year-over-year. U.S. sales totaled $1.2 billion, rising 2%, while international sales reached $1.7 billion, reflecting a 6% growth. Net income decreased 3% to $356 million, or $0.69 per diluted share, due to special items totaling $75 million. The company anticipates low single-digit sales growth for the full year and expects U.S. GAAP earnings between $2.41 and $2.44 per share. Baxter also emphasized its commitment to kidney health and corporate responsibility initiatives.
Baxter International (NYSE:BAX) acknowledges the results of a multicenter study from the OxirisNet Registry, focusing on COVID-19 patients treated with the Oxiris filter. The study indicated a significant reduction in serum IL-6 levels and improvements in organ function, correlating with a decrease in ICU mortality rates compared to historical controls. However, due to the study's observational design, no causal relationships can be established. The findings emphasize the potential of Oxiris in treating critically ill patients, paving the way for further research.
Baxter International Inc. (NYSE:BAX) supports findings from an ongoing study on critically ill COVID-19 patients, demonstrating the importance of indirect calorimetry in accurately assessing nutritional needs in ICU settings. The study, which analyzed 22 patients over 21 days, revealed that traditional predictive equations significantly understate patients' resting energy expenditure (REE). Notably, after the first week, average REE was 150% of predictions, with some cases reaching double. These findings underscore the risks associated with both over- and under-feeding in this vulnerable population.
Baxter International (NYSE:BAX) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on November 9, 2020. Jay Saccaro, the CFO, is set to speak at 11:45 a.m. Eastern Time. Investors and interested parties can access the live presentation and replay through November 9, 2021, on www.baxter.com. Baxter's extensive portfolio of medical products supports millions of patients and healthcare providers globally, emphasizing their commitment to transformative healthcare innovations.
Baxter International Inc. (NYSE:BAX) supports interim findings from a study on the nutritional needs of COVID-19 patients in ICU, which highlights the inaccuracies of predictive equations in estimating energy requirements. The study of 22 U.S. patients indicates that patients experienced progressive hypermetabolism and variability in resting energy expenditure (REE) over their ICU stay. Baxter's Q-NRG+ technology aims to address these challenges by providing accurate and personalized nutrition insights, essential for improving patient outcomes.